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ABSTRACT
Diabetes mellitus is associated with bone loss. Patients with type 2 diabetes are frequently treated with oral antidiabetic drugs such as 
sulfonylureas, biguanides, and thiazolidinediones. Rosiglitazone treatment has been shown to increase adipogenesis in bone marrow 
and to induce bone loss. In this study we evaluated the effect of in vivo and in vitro treatment with metformin on bone marrow 
progenitor cells (BMPCs), as well as the involvement of AMPK pathway in its effects. The in vitro effect of coincubation with metformin 
and rosiglitazone on the adipogenic differentiation of BMPCs also was studied. In addition, we evaluated the effect of in vivo metformin 
treatment on bone regeneration in a model of parietal lesions in nondiabetic and streptozotocin-induced diabetic rats. We found that 
metformin administration both in vivo and in vitro caused an increase in alkaline phosphatase activity, type I collagen synthesis, 
osteocalcin expression, and extracellular calcium deposition of BMPCs. Moreover, metformin significantly activated AMPK in undiffer­
entiated BMPCs. In vivo, metformin administration enhanced the expression of osteoblast-specific transcription factor Runx2/Cbfal and 
activation of AMPK in a time-dependent manner. Metformin treatment also stimulated bone lesion regeneration in control and diabetic 
rats. In vitro, metformin partially inhibited the adipogenic actions of rosiglitazone on BMPCs. In conclusion, our results indicate that 
metformin causes an osteogenic effect both in vivo and in vitro, possibly mediated by Runx2/Cbfal and AMPK activation, suggesting a 
possible action of metformin in a shift toward the osteoblastic differentiation of BMPCs. © 2010 American Society for Bone and Mineral 
Research.
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Introduction
L
ong-standing diabetes mellitus has been associated with 
bone loss that can cause an increase in fracture risk/1 3> It has 
been suggested that these diabetes-associated bone alterations 
could be, at least in part, due to a pathologic accumulation of 
advanced glycation end products (AGEs) on bone extracellular 
matrix proteins.14'51 Different insulin sensitizers such as metfor­
min and thiazolidinediones (used as monotherapy or in 
combination) have proved to be efficient for the treatment of 
type 2 diabetes mellitus/61 It has been demonstrated previously 
that thiazolidinediones (e.g., rosiglitazone and netoglitazone) 
not only activate peroxisome proliferator-activated receptor 
gamma (PPAR7) but also suppress the expression and action of 
the osteoblast-specific transcription factor Cbfal.(7) Moreover, 
there is evidence that thiazolidinediones promote bone marrow 
stromal cell adipogenesis and inhibit osteogenesis.(8 10) 
Mice treated in vivo with thiazolidinediones decreased 
their bone mineral content, bone formation, and trabecular 
bone volume and increased adipogenesis/8,9,111 On the 
other hand, in patients with type 2 diabetes mellitus, metformin 
and sulfonylureas have been associated with a decreased 
risk of fracture/11 However, there is little information 
regarding the effect of these antidiabetic drugs on bone 
metabolism.
Our group has recently demonstrated that metformin causes a 
direct osteogenic action in a model of osteoblasts in culture/121 
These actions include a dose-dependent increase in cell 
proliferation, type I collagen production, alkaline phosphatase 
(ALP) activity, and mineral deposition. These osteogenic actions 
of metformin appear to be mediated by an increase in the 
expression of nitric oxide synthases and in the activity of 
extracellular regulated kinases. Recently, Kanazawa and collea- 
gues(13) have confirmed these results and suggested that 
metformin can induce the differentiation and mineralization of 
osteoblasts via activation of AMPK pathway and induction of 
endothelial nitric oxide synthase (eNOS) and bone morphoge­
netic protein-2 (BMP-2) expression.
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Bone is a highly dynamic tissue/141 Cells of the bone marrow 
microenvironment appear to share common mesenchymal 
progenitor cells, which present the ability to differentiate into 
various cell types such as osteoblasts, adipocytes, and 
chondrocytes.115 171 In this context, bone marrow metabolic 
conditions are determinants of the biologic balance between 
osteoblast-mediated bone formation and marrow adipogen- 
esis.(15) Diverse factors such as endogenous hormones and drug 
treatment can affect this delicate balance, modifying the 
osteoblast-adipocyte ratio in the bone marrow/151 In this 
context, a recent study has underlined the importance of PPAR7 
in controlling the adipocyte-osteoblast relationship within the 
bone marrow cavity/181
In the present work, we have evaluated the in vivo and in vitro 
actions, as well as the possible mechanism of action, of 
metformin on bone marrow mesenchymal progenitor cells 
(BMPCs) and the effect of in vitro cotreatment with metformin 
and rosiglitazone on BMPCs. We also have investigated the 
effect of in vivo metformin administration on bone tissue 
regeneration in control nondiabetic and streptozotocin-induced 
diabetic rats.
Materials and Methods
Animal treatment
Adult male Sprague-Dawley rats (190 to 21 Og) were used. 
Animals were maintained in a temperature-controlled room at 
23°C with a fixed 12 hour light:! 2 hour darkness cycle, and fed 
standard rat laboratory chow and water ad libitum. All 
experiments on animals were done in conformity with the 
Guidelines on Handling and Training of Laboratory Animals 
published by the Universities Federation for Animals Welfare 
(1992)/191 In half the animals, diabetes was induced by a single 
intraperitoneal injection of streptozotocin at a dose of 55 mg/kg 
freshly dissolved in citrate buffer (0.05 M, pH 4.5)/201 Four days 
later, blood glucose was assayed, and diabetes was verified in all 
streptozotocin-treated animals.
Animals then were divided into four groups of 10 animals per 
group. Control nondiabetic rats (C) and diabetic rats (D) received 
water ad libitum; metformin-treated nondiabetic rats (M) and 
metformin-treated diabetic rats (DM) received 100 mg/kg per 
day of metformin (Quimica Montpellier, Buenos Aires, Argentina) 
in drinking water for 2 weeks.
Serum glucose was measured by the glucose oxidase method; 
serum triglyceride and cholesterol were measured by a 
commercial kit (Wiener Laboratories, Rosario, Argentina).
Bone reossification model
The effect of metformin on the process of bone repair was 
assessed by a reossification model, as described previously/211 
Animals were divided into four groups as described earlier. 
Briefly, all the animals were anesthetized by intraperitoneal/ 
intramuscular injection of 0.12mL/100g of body weight with 
62.5mg/mL ketamine hydrochloride and 6.25 mg/mL xylazine 
(Laboratorios Richmond, Buenos Aires, Argentina). Circular 
craniotomy defects of 1.0 mm diameter were made in parietal 
bones of animals with a cylindrical low-speed carbide bur. 
Animals were maintained in a thermostatized atmosphere with 
12 hour light-dark cycles and fed with commercial rat chow for 
15 days.
Histologic examination of bone reossification
After 15 days of metformin treatment, rats were sacrificed under 
anesthesia by neck dislocation, and the parietal bones were 
processed for histologic and quantitative histomorphometric 
analysis. Parietal bones were fixed in 10% formalin and 
decalcified in 10% EDTA. The bones were embedded in paraffin, 
and 5 pm sections were obtained with an SM 2000R Leica (Leica 
Microsystems, Wetzlar, Germany) microtome. The sections were 
stained with hematoxylin and eosin (H&E) or tartrate-resistant 
acid phosphatase (TRAP) (Sigma, St. Louis, MO, USA) histo­
chemistry to specifically identify osteoclasts/221 Photographs 
were taken with a Nikon Coolpix 4500 digital camera on an 
Eclipse E400 Nikon microscope (Nikon, Tokyo, Japan). Images 
were analyzed using the Image J program (www.macbiophoto- 
nics.ca/imagej) with a microscope scale plugin. Reossification 
was calculated as the ratio between either the newly reossified 
area or thickness and the average bone thickness (H&E). In 
addition, osteoblastic density was evaluated by counting the 
number of osteoblasts per unit of reossification surface, 
osteocyte density was assessed by counting the number of 
osteocytes per area of newly reossificated bone, and osteoclastic 
density was calculated as the positive TRAP area per square 
millimeter of newly reossificated bone tissue (Oc/mm2)/221
Bone marrow progenitor cell (BMPC) isolation and 
incubation
BMPCs were obtained from control nondiabetic and metformin- 
treated rats as described previously/161 Briefly, animals were 
sacrificed under anesthesia by rapid neck dislocation. Bone 
marrow cells were collected by flushing the femurs and tibiae of 
the animals with Dulbecco's modified essential medium (DMEM) 
(Invitrogen, Buenos Aires, Argentina) under sterile conditions. 
The resulting suspension was seeded in a 25 cm2 tissue culture 
flask and incubated in DMEM supplemented with penicillin 
(lOOUI/mL), streptomycin (100 pg/mL), and 10% fetal bovine 
serum (FBS) (Natocor, Córdoba, Argentina) at 37 C in a 
humidified atmosphere with 5% CO2 and 95% air. Nonadherent 
cells were removed by changing the medium after 24 hours. The 
culture medium was changed twice a week. When cells reached 
confluence (after 10 to 15 days), the cell monolayer was 
detached using 0.12% trypsin and 1 mM EDTA and subcultured 
in tissue culture plates. After 5 days, the basal level of alkaline 
phosphatase activity (i.e., prior to osteogenic differentiation) was 
evaluated as described below.
In order to investigate the role of AMPK as a signal­
transduction pathway for metformin in BMPCs, cells were 
plated onto six-well plates and cultured until 70% confluence. 
They were then serum-starved for 2 hours and incubated 
with the doses of metformin indicated in the figure legends for 
60 mintes. At the end of this incubation period, the cells 
were processed by immunofluorescence and Western blotting 
to evaluate expression and activation of AMPK, as described 
below.
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Osteogenic differentiation of rat BMPCs
BMPCs were plated at a density of 5 x 104 cells/well in 24-well 
plates containing 10% FBS-DMEM medium and incubated at 
37C. After cells reached confluence, they were induced to 
differentiate into osteoblasts using an osteogenic medium 
(DMEM-10% FBS containing 25p,g/mL ascorbic acid and 5 mM 
sodium p-glycerol-phosphate) fora further 15 or 21 days.(12,The 
medium was changed twice a week. Osteoblastic differentiation 
was evaluated by measuring alkaline phosphatase activity, type I 
collagen production, osteocalcin expression, and extracellular 
calcium deposition, as described below.
After 15 days of osteogenic differentiation, cell monolayers 
were washed with phosphate-buffered saline (PBS) and lysed 
with 200 p.L 0.1% Triton-XIOO. An aliquot of 100 p.L of the lysate 
was used to evaluate alkaline phosphatase activity by the 
hydrolysis of p-nitrophenylphosphate (p-NPP) intop-nitrophenol 
(p-NP) at 37C for 1 hour. The absorbance of p-NP was recorded 
at 405 nm/23) Aliquots of the same extract were used for protein 
determination by Bradford's technique/241 Type I collagen 
production was evaluated as reported previously/251 Briefly, 
after 21 days of osteogenic differentiation, cell monolayers were 
fixed with Bouin's solution and stained with Sirius red dye for 
1 hour. The stained material was dissolved in 1 mL 0.1 N sodium 
hydroxide, and the absorbance of the solution was recorded at 
550 nm. Osteocalcin expression was evaluated after 21 days of 
culture by Western blotting. Extracellular calcium deposits 
(mineralization nodules) also were evaluated after 21 days of 
culture using alizarin S red staining/261 Stained calcium deposits 
were extracted with 1 mLO.l N sodium hydroxide, recording the 
optical density at 548 nm. Alternatively, stained cultures were 
observed using a Nikon microscope and photographed.
Adipogenic differentiation of rat BMPCs
To initiate adipocyte differentiation, BMPCs were grown to 
confluence in 24-well plates in DMEM-10% FBS. Differentiation 
to adipocytes was induced by further culturing the cells for 
10 days with DMEM-10% FBS supplemented with 0.5 p,M 
rosiglitazone (Quimica, Montpellier, Argentina), 1 p.M dexa­
methasone (Decadron, Sidus, Argentina), and 200 nM insulin 
(Lilly, Buenos Aires, Argentina). In certain experiments, rosigli­
tazone was substituted by 3-isobutyl-l-methylxanthine (IBMX) 
0.5 mM as inducer of adipogenesis. To evaluate the effect of 
metformin on rosiglitazone-induced adipogenesis, in some cases 
cells were simultaneously incubated with metformin (1 or 10 pM) 
and 0.5 pM rosiglitazone for 10 days. After these culture periods, 
intracellular triacylglyceride deposits were analyzed with an 
enzymatic commercial kit (Wiener, Rosario, Argentina). Briefly, 
lOOpL 0.1% Triton-XIOO cell monolayer lysates were incubated 
for 1 hour with reaction buffer according to the manufacturer's 
instructions, and absorbance was measured at 505 nm. Aliquots 
of the same extract were used for protein determination by 
Bradford's technique/241 In some cases, after 10 days of 
differentiation, the medium was aspirated, and nonlysed cells 
were stained with oil red O to detect accumulation of 
intracellular lipid deposits. The cell monolayers were observed 
using an Eclipse E400 Nikon microscope and photographed with 
a Nikon Coolpix 4500 digital camera.
Western blot analysis
BMPCs were grown to confluence in 6-well plates in DMEM-10% 
FBS and then differentiated into either osteoblasts or adipocytes 
as described earlier. At the end of different culture periods, cells 
were lysed in Laemmlis buffer/271 These lysates were heated to 
100 C for 3 minutes, and 30 pg of protein was subjected to 12% 
SDS-PAGE.The separated proteins then were transferred to PVDF 
membranes. After washing and blocking, the membranes were 
incubated overnight at 4 C with an antibody directed against 
Cbfal/Runx2 or osteocalcin (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) for evaluation of osteoblastogenesis or against 
PPAR7 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 
evaluation of adipogenesis. In order to normalize results, all blots 
were stripped and reprobed with an anti-[3-actin antibody 
(Sigma, St. Louis, MO, USA). In experiments designed to 
investigate AMPK, blots were probed with either an anti-total 
AMPK or anti-P-AMPK antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) to assess the in vitro mechanism of action of 
metformin/131 Blots were developed by an enhanced chemilu­
minescence method. The intensity of the specific bands was 
quantified by densitometry after scanning of the photographic 
film. Images were analyzed using the Scion beta 2 program 
(Scion Corporation, Frederick, MD, USA).
Immunofluorescence microscopy
Subconfluent osteoblasts grown on glass coverslips were 
washed in PBS, fixed with 4% paraformaldehyde in PBS 
(10 minutes at room temperature), and permeabilized with 
methanol for 4 minutes at —20'3C.(28) Nonspecific binding sites 
were blocked with 1% bovine serum albumin (BSA) in PBS for 
2 hour. Cells then were incubated with anti-AMPK or anti-P- 
AMPK antibodies (1:100 in blocking buffer) overnight at 4G 
After washing, cells were exposed toa fluorescein isothiocyanate 
(FITC) conjugated secondary antibody (1:200) for 1 hour at room 
temperature. Cells were mounted in VECTA-SHIELD Mounting 
Medium with 4',6-diamidino-2-phenylindole (DAPI) and observ­
ed with a Nikon fluorescence microscope. Fluorescence intensity 
of each cell was semiquantified with an MBF-lmage J program 
{www.macbiophotonics.ca) using green global calibration.
Statistical analysis
Results are expressed as the mean ± standard error of the mean 
(SEM) and were obtained from three separate experiments 
performed in sextuplícate. Differences between the groups were 
assessed by one-way analysis of variance (ANOVA) using the 
Tukey post hoc test. For nonnormally distributed data, the non 
parametric Kruskal-Wallis test with the Dunn post hoc test was 
performed using GraphPad In Stat version 3.00 (Graph Pad 
Software, San Diego, CA, USA), p < .05 was considered significant 
for all statistical analyses.
Results
In vitro direct effect of metformin on BMPC osteoblastic 
differentiation
In a first series of experiments, we evaluated the direct effect of 
metformin on BMPC differentiation to osteoblastic phenotype. 
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BMPCs from control rats were incubated in osteogenic medium 
containing increasing doses of metformin (0.5 to 10 pM). These 
doses are in the order of the plasma concentrations of metformin 
found in patients (10pM).(29) Osteogenic differentiation was 
evaluated by assessing the expression of extracellular type I 
collagen, ALP activity, and mineral deposits after 7, 15, and 
21 days of culture. No differences were observed between 
control and metformin-treated cells after the first week of 
osteogenic differentiation (data not shown). After 15 days of 
differentiation, metformin significantly increased ALP activity, in 
a dose-dependent manner (Fig. 1A). As explained in "Materials 
and Methods," production of type I collagen was first 
qualitatively assessed by Sirius red staining of cell monolayers 
(see Fig. IB) and then quantified by extraction of the dye. As 
shown in Fig. 1C, metformin dose-dependently increases 
collagen production between 0.5 and lOpM. Additionally, 
collagen production of metformin-treated cells is significantly 
greater than in untreated cells at all metformin doses tested. This 
effect correlates with a greater mineralizing activity of 
metformin-treated cells, as evaluated by alizarin red staining 
of the cell monolayer (see Fig. ID) and its quantification after 
extraction (see Fig. If). After 21 days of osteogenic differentia­
tion, extracellular calcium deposits (nodules of mineralization) 
were increased at all metformin doses tested versus untreated 
cells, with the highest calcium deposits obtained at 10 pM of 
metformin (160±18% basal; see Fig. If).
Metformin partially abolishes rosiglitazone-induced 
adipogenesis
To determine the effect of metformin on rosiglitazone-induced 
adipogenesis, BMPCs were committed to differentiate into 
adipocytes by treatment for 10 days with either rosiglitazone 
alone (0.5 pM) or rosiglitazone plus metformin (1 or 10 pM). 
Adipogenesis was evaluated through the enzymatic determina­
tion of intracellular lipid deposits in cell extracts and the staining 
of lipid droplets with oil red O in cell monolayers. BMPCs cultured 
in adipogénie medium without the addition of rosiglitazone 
presented intracellular lipid content below the detection limit of 
our enzymatic assay (data not shown). We found that metformin 
caused a significant dose-dependent decrease in the rosiglita­
zone-induced accumulation of intracellular triacylglycerides 
(Fig. 2A) and of lipid droplets (see Fig. 2B) when compared 
with cells treated with rosiglitazone alone. In parallel experi­
ments in which we substituted rosiglitazone with IBMX as 
inducer of adipogenesis, metformin also was found to induce a 
dose-dependent decrease in the accumulation of intracellular 
lipids (data not shown).
In vivo administration of metformin increases the in vitro 
osteoblastic differentiation of BMPCs
We next evaluated the effect of in vivo treatment with metformin 
on the osteogenic potential of BMPCs in vitro (i.e., the ex vivo 
effect of metformin on BMPCs). This drug was administered to 
rats in drinking water, as described in "Materials and Methods." 
After 15 days, BMPCs were obtained from control and 
metformin-treated rats and cultured until they reached 
confluence. After the first passage, the basal-specific activity
Control 0 5 pM 1 pM 10 pM
Fig. 1. Effect of metformin on osteoblastogenesis. BMPCs isolated from 
control rats were cultured in an osteogenic medium for 15 or 21 days 
with or without different doses of metformin. After 15 days, ALP (A) 
and type I collagen production (B, Q were measured to evaluate 
osteoblastic differentiation. After 21 days of culture, mineralization 
was assessed by the alizarin red method (D, E). Basal ALP activity 
(0 pM metformin) = 4.2 ±0.5 nmol p-nitrophenol/mg protein per minute. 
Basal type I collagen production (OpM metformin) =4.2 ±0.2 pg 
collagen/mg protein. Values are expressed as mean±SEM. *p < .05, 
”p<.01.
of ALP was assessed for all cultures (i.e., prior to osteogenic 
differentiation). Cells obtained from metformin-treated rats 
showed a significantly greater expression of ALP (8.9 ± 0.8 nmol 
p-nitrophenol/mg protein per minute) than cells obtained from 
control (untreated) rats (4.7 ±0.2 nmol p-nitrophenol/mg 
protein per minute; p < .05).
We also evaluated the ex vivo effect of metformin on BMPC 
osteogenic potential after 15 or 21 days of incubation of cells
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Rosiglitazone 0 5 pM +
Metformin 1 pM
Metformin 10 pM +
Rosiglitazone 0.5 pM +
Metformin 1 pM
Metformin 10 pM
Fig. 2. Effect of metformin on rosiglitazone-induced adipogenesis. BMPCs isolated from control rats were induced to differentiate into adipocytes with a 
medium containing rosiglitazone, insulin, and dexamethasone in the presence or absence of different doses of metformin. After 10 days of culture, cell 
extracts were obtained, and intracellular triacylglyceride accumulation was quantified as described in "Materials and Methods" (A). Alternatively, lipid 
droplets were stained with oil red O in whole cells and observed with a light microscope (B). Basal triacylglyceride content (0 pM metformin) = 178 ± 6 pg/ 
mg protein. Values are expressed as mean ±SEM. *p < .05, **p < .01.
obtained from either control or metformin-treated rats in an 
osteogenic medium. After 15 days of differentiation, we found 
that BMPCs from metformin-treated rats expressed higher levels 
of ALP than BMPCs from control rats (Fig. 3A) and a significant 
increase in type I collagen production (see Fig. 38). Similarly, after 
21 days of differentiation, we found a significant increase in 
osteocalcin expression (see Fig. 3C) and in the formation of 
mineralization nodules (see Fig. 3D) in BMPCs from metformin- 
treated rats in comparison with BMPCs from control rats.
Metformin increases bone healing in diabetic and 
nondiabetic rats
We used a model of bone reossification to evaluate the effect of 
the in vivo administration of metformin on bone tissue 
regeneration. To this effect, we performed uniform craniotomy 
defects in parietal bones as described in "Materials and 
Methods" and allowed them to heal for 15 days. After this 
period of time, this bone—in which mechanical loading can be 
expected to be low—went through different stages in the repair 
of intramembranous bone(30): namely, an inflammatory infiltrate 
followed by formation of granulatory and fibrous tissue and 
osteoclastic resorption of bone fragments and, finally, bridging 
of the lesion by a hard callus of intramembranous primary bone. 
In the time span of our experiments, we were unable to find any 
significant remodeling of the primary bone callus to form mature 
cancellous bone.
In our experiments, both control (nondiabetic) and strepto- 
zotocin-induced diabetic rats were used. The metabolic status of 
the different animal groups was assessed by the biochemical 
parameters showed in Table 1. At the time of sacrifice, diabetic 
animals (treated or untreated with metformin) showed a 15% 
reduction in body weight. Plasma glucose levels of the D and DM 
groups were significantly elevated. In addition, diabetic animals 
had significantly elevated cholesterol and triglyceride levels 
compared with the nondiabetic control and metformin-treated 
groups.
We stained the tissue sections with H&E to evaluate the 
following parameters: relative quantity of newly reossified bone 
(Fig. 4A-D), the number of osteocytes immersed in reossified 
bone tissue (see Fig. 4£), and the number of osteoblasts on the 
surface of reossified bone (see Fig. 48). In addition, TRAP staining 
was performed to evaluate the proportion of reossified surface 
covered by osteoclasts (see Fig. 4F-J). Histomorphometric 
analysis of the tissue sections is shown in Table 2. Diabetic 
rats showed a decrease in the thickness, area, and osteoblast and
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Fig. 3. Ex vivo effect of metformin on the osteoblastic potential of BMPCs. BMPCs isolated from control or metformin-treated (lOOmg/kg per day) rats 
were incubated in an osteogenic medium for 15 days, after which ALP activity (A) and type I collagen production (B) were measured, or BMPCs were 
cultured for 21 days, after which osteocalcin (C) and mineralization nodules (D) were evaluated. Values are expressed as mean ±SEM. *p < .05.
osteocyte density, of newly reossified bone when compared with 
nondiabetic rats. Metformin treatment induced a significant 
increase in the thickness and area of reossification in both 
control and diabetic rats without affecting osteoblast and 
osteocyte density. Interestingly, a significant 3.8-fold increase 
was observed in the TRAP activity of nondiabetic rats after 
15 days of treatment with metformin.
Effect of ex vivo metformin treatment on osteoblastic 
and adipogenic transcription factors
We next evaluated possible changes in the expression of the two 
major transcription factors for osteoblastogenesis and adipo­
genesis, Cbfa1/Runx2 and PPARy (Fig. 5). BMPCs from either 
control or metformin-treated rats were cultured in an osteogenic 
or adipogenic medium for the times indicated in the figures. 
Western immunoblot analysis showed that when compared with 
BMPCs from basal conditions (undifferentiated cells, time 0), 
BMPCs from metformin-treated rats expressed significantly more 
of the osteoblastic transcription factor Runx2 (see Fig. 5A) but a 
similar amount of the adipogenic transcription factor PPARy (see 
Fig. 58). In addition, there was a time-dependent increase in 
Runx2 expression after 15 and 21 days of osteoblastic 
differentiation. In contrast, no changes in PPARy expression 
were seen after 10 days of adipogenic differentiation in BMPCs 
from metformin-treated or untreated rats.
Effect of metformin on the AMPK signaling 
pathway in BMPCs
In order to investigate possible signal-transduction mechanisms, 
we assessed the in vitro and ex vivo effect of metformin on AMPK 
signaling. We first studied the direct effect of metformin on the 
activation of AMPK in BMPCs derived from control rats by both 
immunofluorescence and Western blot techniques.
When analyzed by immunofluorescence, total AMPK was 
found to localize in the nucleus and the cytoplasm of both 
untreated and metformin-treated cells, showing no observable
Table 1. Weight and Plasma Profile after 15 days of Treatment with or without Metformin 100 mg/kg in Control Nondiabetic and 
Diabetic Animals
Group Weight (g) Glucose (mg/dL) Cholesterol (mg/dL) Triglycerides (mg/dL)
Control 190 ±9 110 ± 10 43 ±4 45 ±4
Control + metformin 187 ±6 103±5 36 ±1 37 ±3
Diabetic 160±7* 257 ±30* 59 ±2*** 62 ±5***
Diabetic ± metformin 155 ±8*** 213 ±23*** 35 ±3 48 ±4
Values are mean ±SEM, n = 10 per group.
*p < .05 versus C group, 
**p < .05 versus C + M group.
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Fig. 4. Bone repair in a bone reossification model. A 1 mm circular bone defect was performed under anesthesia in the parietal bone of control 
nondiabetic rats (A, F), metformin-treated control rats (100 mg/kg per day) (B, G), streptozotocin-induced diabetic rats (C,H), or metformin-treated diabetic 
rats (D, /). After 15 days, all animals were sacrificed, and the parietal bones were examined by the histologic procedures detailed in "Materials and 
Methods." Bone sections were stained with hematoxylin & eosin (A-E) or analyzed for TRAP activity (F-J) to assess new bone formation (arrows), as well as 
the density of osteocytes (E), osteoblasts (E), and osteoclasts (J). Panels (E) and (J) (control rats) are representative images of osteoblasts, osteocytes, and 
osteoclasts.
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difference in fluorescence intensity in either case (data not 
shown). However, when we probed with an antibody that 
recognizes the phosphorylated Thr172 in the a-subunit of AMPK, 
we found different results (Fig. 6A). Metformin increased P- 
AMPK-associated fluorescence in both the cytoplasm and the 
nucleus. A semiquantitation of P-AMPK- associated fluorescence 
in metformin-treated BMPCs showed that P-AMPK expression 
was increased 1.5-fold versus untreated control cells in both the 
nucleus and the cytoplasm.
The results obtained by immunofluorescence were further 
confirmed by Western immunoblotting (see Fig. 68). After 1 hour 
of incubation, lOOp.M metformin significantly increased by 1.6- 
fold the P-AMPK:AMPK ratio in BMPCs.
In other experiments we obtained BMPCs from both control 
and metformin-treated rats and submitted them to an 
osteogenic differentiation medium for 0, 15, or 21 days. After 
these periods of time, we evaluated both AMPK and P-AMPK in 
cell extracts by Western blotting. We found that ex vivo 
metformin induced a significant 2.8-fold increase in the P- 
AMPK:AMPK ratio after 21 days, with no observable difference for 
0 or 15 days (see Fig. 6C).
Discussion
Bone is a complex tissue containing several cell types that is 
continuously undergoing a process of self-renewal and repair 
termed bone remodeling.1''41 In aged people and in patients 
suffering from diabetes mellitus, bone remodeling is altered, and 
consequently, there is an increased skeletal fragility and fracture 
risk.'1-31
Sections of decalcified bone were stained with haematoxylin-eosin or tartrate resistance acid phosphatase (TRAP) (for osteoclasts) and quantitated 
using Image J program. Values are expressed as mean±SEM of sections.
*p < .05 vs. C group;
#p < .05 vs. C + M group;
*p < .05 vs D.
Table 2. Quantitative Histomorphometric Analysis of Tissue Sections of the Lesion Area From Parietal Bones
Control Control ± Metformin Diabetic Diabetic ± Metformin
Reossification thickness/Bone thickness [%] 30 ±1 46 ±3* 19 ± 1 *'# 43 ± 4*'#'*
Reossification area/Bone thickness [mm] 69 ±9 143 ±11 * 16±4*'# 160 ±10*'*
Osteocyte number/Reossification area [mm 2] 2440 ±194 2943 ±226 993±132*'# 854±103*'#
Osteoblast number/Reossification length [mm ] 145 ± 11 156± 16 60 ± 6*'# 49 ± 9*'#
TRAP area/Reossification area [%] 2.3 ±0.4 8.8 ±1.7* 2.9 ± 0.1# 2.4±0.9#
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Fig. 5. Expression of Runx2 and PPAR-y in BMPCs from control or 
metformin-treated rats. BMPCs isolated from either control or metfor- 
min-treated (lOOmg/kg per day) rats were cultured in osteogenic or 
adipogenic medium for the periods of time indicated in the figures. The 
expression of osteogenic transcription factor Runx2 and the housekeep­
ing protein actin (A) or adipogenic transcription factor PPAR-y and actin 
(B) was evaluated by Western immunoblot. The blots were quantified 
with the Scion beta 2 image program, data were normalized against actin, 
and the corresponding values are shown as bar graphs. Values are 
expressed as mean ±SEM. *p < .05.
Recently, considerable interest has focused on bone marrow 
mesenchymal cells for different applications in the field of bone 
tissue engineering. Prior studies have demonstrated that in the 
bone marrow microenvironment, reciprocal regulation of PPARy 
and Runx2 underlies the age-related increase in both marrow 
adiposity and bone loss.(18) Since an increase in bone marrow 
adipocytes is associated with different conditions that lead to 
bone loss/151 and under the perspective of recent studies that 
indicate that thiazolidinediones not only inhibit osteogenesis but 
also stimulate adipogenesis/71 evaluation of the actions of 
metformin—a widely used antidiabetic drug—on bone marrow 
adipogenic and osteogenic differentiation is of clinical relevance.
Under proper stimuli, BMPCs have the capability to differ­
entiate into different cell types such as osteoblasts, chondro­
cytes, and adipocytes. The commitment to differentiate into a 
specific cell type can be influenced by different agents such as 
cytokines, growth factors, hormones, or drugs. We have 
previously demonstrated that metformin enhances the prolif­
eration, differentiation, and mineralization of osteoblast cell lines 
in culture/121 In the present study we have found that metformin 
causes a direct increase in BMPC osteoblastic maturation: It 
stimulates both ALP activity and type I collagen synthesis after 
15 days of culture, as well as the deposition of extracellular 
mineral nodules after 21 days of culture (see Fig. 1). We also have 
found that the osteogenic stages of development for BMPCs 
from control rats are similar to those previously described by 
other authors for mesenchymal stem cells and osteoblastic cell 
lines/31 331 Those authors have reported that initially the 
proliferation of osteoblasts coincides with production of type I 
collagen and fibronectin and is followed sequentially by an 
enhanced expression of ALP and extracellular calcium deposi- 
tion/31,33) The increased expression of ALP mediates the 
formation of insoluble phosphate salts, thereby initiating the 
calcification process/311
In this study we have found that metformin also increases the 
ex vivo osteogenic potential of BMPCs; that is, the in vivo 
administration of metformin enhances BMPC osteoblastic ALP, 
type I collagen, osteocalcin, and mineral deposition in vitro (see 
Fig. 3) probably by increasing the expression of the Runx2/Cbfal 
transcription factor (see Fig. 5). Additionally, we created a parietal 
bone defect in nondiabetic and streptozotocin-induced diabetic 
rats, either untreated or treated with metformin. In untreated 
animals, we found that the diabetic state per se induces a 
significant decrease in bone healing, as evaluated by histomor- 
phometric analysis (see Fig. 4 and Table 2). These results are in 
agreement with the previous report of Santana and collea­
gues/211 We also observed that metformin causes an increase in 
bone reossification at the lesion site in both diabetic and 
nondiabetic animals (see Fig. 4 and Table 2). In addition, 
metformin increases total osteoclastic activity in nondiabetic 
animals. These results with metformin probably reflect a 
concerted increase in bone formation and remodeling at the 
lesion site in a precisely regulated process that involves the 
localized coupling of osteoclasts with osteoblasts/22,341 Although 
we found that metformin induces an increase in bone 
reossification, it does not alter the glycemic profiles of either 
diabetic or nondiabetic rats (see Table 1). These results, as well as 
the results of our previous studies with osteoblastic cells in 
culture/121 provide strong evidence that metformin has a direct 
osteogenic effect on bone cells. Our present in vivo and ex vivo 
findings are in agreement with previous clinical studies by other 
authors that indicate that metformin treatment could be 
associated with a decrease in the fracture risk of diabetic 
patients/11
We also performed studies to elucidate the mechanism of 
action of metformin on bone cells. Our present findings show 
that metformin directly enhances the phosphorylation/activa- 
tion of AMPK, as assessed by immunofluorescence and Western
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Fig. 6. Effect of metformin on AMPK activation in BMPCs derived from contol or metformin-treated rats. BMPCs were isolated from untreated control rats 
(A, 8). After reaching confluence, cells were serum starved for 2 hours and further incubated for 1 hour in the absence (control) or the presence of 100 p.M 
metformin. After this incubation period, cells were processed by immunofluorescence (A) or Western immunoblot (B) to detect AMPK and/or P-AMPK. In 
other experiments, BMPCs were isolated from untreated control or metformin-treated rats (C). After they reached confluence, cells were induced to 
differentiate in an osteogenic medium for 0,15, or 21 days. At the end of this culture period, cells were extracted with Laemmli buffer and processed for P- 
AMPK and AMPK detection by Western immunoblot. The blots were quantified with the Scion beta 2 image program, and the P-AMPK:AMPK ratio was 
determined for each experimental condition. Data are representative of three different experiments. *p < .05 versus control.
B
blotting in BMPCs. These results agree with the previous 
observations of Kanazawa and colleagues1131 in MC3T3E1 
osteoblastic cells. These authors showed that metformin- 
induced osteoblastic differentiation was associated with AMPK 
activation and with enhanced expression of eNOS and BMP-2 
mRNA. Using this same osteoblastic cell line, we also have 
demonstrated previously1121 that metformin exerts a direct 
osteogenic effect associated with MAPK activation and an 
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increase in e/iNOS protein expression. In our present results, we 
have found that BMPCs obtained from metformin-treated rats 
and submitted to an osteogenic medium for 15 to 21 days 
express significantly higher levels of osteoblastic markers in 
comparison with BMPCs from untreated rats (see Fig. 3). These 
findings can be associated with a parallel increase in Runx2/ 
Cbfal expression (see Fig. 5/A) and in the phosphorylation/ 
activation of AMPK (see Fig. 6C) after 15 to 21 days of osteogenic 
differentiation. Altogether, our previous and present observa­
tions suggest that metformin can induce commitment of 
osteoprogenitor cells to the osteoblastic phenotype and bone 
formation by exerting direct effects on bone cells. The 
mechanism of action of metformin appears to be mediated 
by MAPK, e/iNOS, and AMPK signaling.
In addition, our present results indicate that metformin at 
clinically relevant doses(29) can partially block the proadipogenic 
effect of rosiglitazone on BMPCs (see Fig. 2); however, treatment 
with metformin does not affect expression of the transcription 
factor PPAFty versus control (see Fig. 58). Rosiglitazone is an 
efficient insulin-sensitizing drug that unfortunately presents 
adipogenic side effects in the bone marrow microenvironment 
and that is administered frequently as monotherapy or in 
combination with other oral antidiabetic drugs such as 
metformin for the treatment of patients with type 2 diabetes 
mellitus.1 2345(6) 78910123Large prospective clinical trials have shown recently 
that rosiglitazone intake is associated with an increased fracture 
rate.(35,36) In the A Diabetes Outcome Progression Trial (ADOPT), 
this was demonstrated in subjects with recently diagnosed type 
2 diabetes, previously naive to oral antidiabetic drugs, who were 
randomized to taking either rosiglitazone, metformin, or 
glyburide as monotherapy for an average 4 years.(35) Fractures 
were seen predominantly in the lower and upper limbs (in the 
hip and wrist). However, it should be noticed that in the present 
studies we have used an in vivo model of parietal bone defects 
that does not support mechanical loading, as is the case for long 
bones. In addition, the healing of the defect used in our study 
occurs in a relatively short period of time (15 days), and the 
reossification process is intramembranous, meaning that its 
healing does not include soft callus formation, as in endochon­
dral bone repair, but involves direct bridging of the lesion by a 
hard callus of primary bone, which is then remodeled into 
mature bone by the combined action of osteoclasts and 
osteoblasts.(30) In our model of bone healing, metformin was 
found to simultaneously increase reossification and osteoclastic 
activity in the lesion site, suggesting a concerted increase in 
bone formation and remodeling.
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In conclusion, our results show that metformin increases the 
osteogenic induction of BMPCs both in vitro and in vivo and 
enhances the process of bone repair in diabetic and nondiabetic 
rats. The osteogenic actions of metformin on BMPCs are 
associated both with an increase in the expression of 
osteoblast-specific transcription factor Runx2/Cbfal and with 
an increase in the phosphorylation of AMPK. Moreover, 
metformin is able to partially inhibit the adipogenic action of 
rosiglitazone on BMPCs. Further investigations are needed to 
elucidate the in vivo significance of the inhibition by metformin 
of rosiglitazone-induced bone marrow adipogenesis.
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